重组人红细胞生成素治疗肾性贫血的临床分析

目的　观察重组人红细胞生成素 (RhEPO)对肾性贫血的治疗作用。方法　根据使用EPO剂量的不同将 39例慢性肾衰竭并血液透析病人分成 4组 ,观察治疗后 2、4、12个月时与治疗前 (0月 )相比红细胞数 (RBC)、红细胞比积 (Hct)及血红蛋白含量 (Hb)的变化。结果　 2 4例使用EPO10 0 - 15 0IU/ (kg·w) (6 0 0 0IU/w - 90 0 0IU/w) ,治疗后RBC、Hct、Hb较治疗前有显著升高 (P≤ 0 .0 0 1) ;5例使用EPO5 0IU/ (kg·w) (30 0 0IU/w) +间断输血患者 ,其RBC、Hct、Hb升高不显著 ;10例不用EPO而单纯输血患者 ,其RBC、Hct、Hb无明显变化 (P >0 .0 5 )。结论　EPO能较好地纠正肾性贫血 ;单纯输血不能治疗肾性贫血     

Victim Help Seeking: Differences Between Intimate Terrorism and Situational Couple Violence

Abstract: Research indicates that two major forms of partner violence exist, intimate terrorism (IT) and situational couple violence (SCV). The current study (N= 389) used a subgroup of women who responded to the Chicago Women’s Health Risk Study to examine whether type of violence experienced is differentially related to formal (e.g., police, medical agencies, counseling) and informal (e.g., family, friends/neighbors) help seeking. IT victims were more likely to seek each type of formal help but were equally or less likely to seek informal help. Findings can inform both family violence research and the development and implementation of social service programs.     

沐舒坦治疗重型颅脑损伤后肺部感染的临床分析

目的:探讨沐舒坦对重型颅脑损伤后肺部感染的治疗作用.方法:选择GCS3～8分重型颅脑损伤后肺部感染的患者90例,随机选45例(实验组)加用沐舒坦治疗,另45例(对照组)未予沐舒坦治疗。所有患者其他治疗措施均基本相同。结果:实验组有42例感染控制,感染控制时间平均(7.8±2.6)d:对照组有35例感染控制,感染控制时间平均(14.1±3.2)d。实验组肺部感染控制率显著高于对照组(P<0.05),而控制感染平均时间显著短于对照组(P<0.05)。结论:沐舒坦治疗重型颅脑损伤后肺部感染有较好的临床疗效,值得临床推广应用。     

射频与中药联合治疗肥厚性咽炎的临床观察

目的 :探讨应用射频与中药联合治疗肥厚性咽炎的疗效。方法 :随机将 16 8例肥厚性咽炎患者分为射频与中药联合治疗组和对照组 ,进行临床观察。结果 :治疗组显效率 76 .3% ,总有效率 10 0 % ,对照组显效率 14 % ,总有效率 82 % ,两组差异有高度显著性 (P<0 .0 1)。 结论 :射频配合中药联合治疗肥厚性咽炎效果显著。     

肝内胆管癌的诊断与治疗(附12例报告)

目的探讨肝内胆管癌发病的诊治方法。方法对我院1990年1月至2003年3月经手术和病理证实的12例肝内胆管癌病例资料进行回顾性分析。结果早期症状无特异性，AFP检查均为阴性，血CEA检查升高显著3例，4例术前诊断为肝内胆管癌，8例误诊，本组行根治性切除5例(41．6％)，姑息性手术7例。结论肝内胆管癌误诊率高，根治性手术率低，熟悉本病的临床特征，B超检查仍是首选方法。术中病理学检查是避免误诊漏诊的重要方法，根治性手术切除是本病最有效的治疗方法。     

急性胰腺炎病因和诊治十年变迁(附725例报道)

急性胰腺炎的病因和早期诊治一直是临床医师关注的问题。目的：探讨近十年来急性胰腺炎病因、诊断和治疗的变迁及其对预后和住院费用的影响，总结急性胰腺炎的治疗经验。方法：采用回顾性临床研究方法，将725例人选患者分为两组．1993年4月～1998年12月就诊的患者为第一组，1999年1月～2002年8月就诊的患者为第二组：分析两组患者病因、诊断指标、治疗方案、并发症、预后、住院费用方面的变化。结果：比较两组病因，两组患胆囊炎胆结石者分别占72．3％和75．8％，高脂血症者分别占25．3％和25．8％，酗酒者分别占10．6％和9．7％。血清淀粉酶水平高于正常上限3倍的总检出率为66．9％．CT诊断总阳性率为92．0％。第一组46．9％的患者应用生长抑素，31．1％的重症患者发生胰腺假性囊肿，2．2％发生胰腺脓肿，死亡率为15．6％。第二组72-3％的患者应用生长抑素，13．2％的重症患者发生胰腺假性囊肿，2．2％发生胰腺脓肿，死亡率为6．5％。第二组的住院费用与第一组相比呈下降趋势，但无显著差异。结论：胆道疾病仍为急性胰腺炎的主要病因，血清淀粉酶和CT是急性胰腺炎较常用和可靠的检查手段。通过早期足量应用胰酶抑制剂(尤其是生长抑素)、肠道去污和改善胰腺微循环，可改善急性胰腺炎的预后，降低并发症发生率、死亡率和住院费用。     

选择性输卵管造影与再通术在诊治阻塞性不孕中的价值(附200例报告)

目的 :评价选择性输卵管插管造影 (SSG)及再通术 (FTR)在输卵管阻塞性不孕中的诊治价值。材料和方法 :先经宫颈对常规子宫、输卵管造影 (HSG)显示输卵管阻塞的 2 0 0例不孕妇女的 380条输卵管进行插管 ,采用选择性插管至输卵管开口处推注 76 %泛影葡胺造影 ,对证实阻塞者行导丝再通术 ,术后随访 2～ 4个月。结果 :插管成功率 99% ,无严重并发症 ,复通率 90 % ,妊娠率 2 1% (4 2 / 2 0 0 )。结论 :SSG和FTR是目前诊治输卵管阻塞性不孕的最好方法     

电气隔离在医疗设备控制系统上的应用

对医疗设备电气控制线路的各种隔离进行了详尽的分析讨论，提出了抑制干扰而采取的电气隔离的技术措施，从而保证医疗设备的正常工作。     

血液透析水处理设备的现状与研发

血液透析水处理设备的进步与发展,直接影响到患者的生存质量。进入21世纪通过国际学术交流与合作,一些诸如双极反渗、直供式、热消毒等新的思维和理念,促进了血液透析水处理设备研制与开发。     

Treatment of osteoporosis in men

Osteoporosis in men is recognised worldwide as an important and increasing public health problem. The causes are more heterogeneous than those in women. About 50% are diagnosed as secondary cases. In some secondary forms of osteoporosis the specific diagnosis results in additional therapeutic options (e.g. androgen therapy in proven hypogonadism). The basic therapy for osteoporosis in men is no different to that in postmenopausal women, namely recommendations for counteracting modifiable risk factors, especially with regard to diet, physical exercise, and calcium and vitamin D supplementation. Concerning specific drug medications, however, even today there is still a therapeutic dilemma in male osteoporosis. While older substances (e.g. calcitonin, fluoride, alfacalcidol) are approved for both sexes, all newer medications have primarily been approved for the treatment of postmenopausal osteoporosis. Health authorities request studies in purely male populations. For new drugs, fracture data are necessary while for new substances within a class (e.g. bisphosphonates), at the very least consistent effects on bone mineral density (BMD) and bone turnover markers are requested. Due to these regulatory rules, ibandronate, teriparatide and strontium ranelate are not approved in the European Union. Some years ago, alendronate was the first bisphosphonate that was approved for the treatment of men with osteoporosis, based on consistent results from two independent male studies using a daily 10 mg dosage. Very recently risedronate was approved by the FDA and EMEA. A randomised, placebo-controlled multicentre trial of 285 male patients showed, after 2 years, a 5.8% increase in lumbar spine BMD in the risedronate 35 mg once weekly group vs 1.2% in the placebo group. In a prospective controlled study on 316 men with primary or secondary osteoporosis we found, after 12 months, a lumbar spine BMD of +4.7% vs +1.0% in controls. The number of patients with one or more new vertebral fractures was 8 in the risedronate group and 20 in the placebo group (a fracture reduction of 60%). Furthermore, we found a significantly smaller decrease in height and a steeper decrease in back pain in the risedronate group. Risedronate is the first oral bisphosphonate available for men with the more comfortable once weekly dosage.